Cassava Sciences (SAVA)

• Market cap: $208M
• 1 day: -4.87%
• 5 days: 11.4%
• 1 month: 106.73%
• 3 months: 104.76%
• 6 months: 198.61%
• Year to date: 56.36%
• 1 year: -85.46%
• 5 years: -56.3%
• 10 years: -67.15%
• Sector: Healthcare
• Industry: Biotechnology

About: Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Employees: 30